部份中文铝碳酸镁西甲硅油处方资料（仅供参考）
商品名：Altacite Plus
药品名：铝碳酸镁西甲硅油混悬液
剂型：混悬液（Suspension）
规格：每5ml含铝碳酸镁500mg，西甲硅油125mg
生产厂家：英国 Peckforton Pharmaceuticals Ltd.
药理毒理
本品有明显抗酸作用，并兼有胃黏膜保护作用，对胆酸也有一定吸附作用，其作用迅速、温和、持久。
适应症
1．慢性胃炎。
2．与胃酸有关的胃部不适症状，如胃痛、胃灼热感（烧心）、酸性嗳气、饱胀等。
用法和用量
口服。一次10毫升，一日4次。餐后1～2小时、睡前或胃部不适时服用。
不良反应
偶见便秘、稀便、口干和食欲缺乏。
注意事项
1.本品连续使用不得超过7天，症状未缓解，请咨询医师或药师。
2.儿童用量请咨询医师或药师。
3.急腹症患者应在医师指导下使用。
4.妊娠期头3个月，严重心、肾功能不全者，高镁血症、高钙血症者慎用。5.如服用过量或出现严重不良反应，应立即就医。
6.对本品过敏者禁用，过敏体质者慎用。
7.本品性状发生改变时禁止使用。
8.请将本品放在儿童不能接触的地方。
9.儿童必须在成人监护下使用。
10.如正在使用其他药品，使用本品前请咨询医师或药师。
药物相互作用
1.服药后1～2小时内应避免服用其他药物，因氢氧化铝可与其他药物结合而降低吸收，影响疗效。
2.如与其他药物同时使用可能会发生药物相互作用，详情请咨询医师或药师。

Altacite Plus
Peckforton Pharmaceuticals
1. Name of the medicinal product
Altacite Plus Suspension
Asda Indigestion Liquid
Sainsbury's Spearmint Indigestion Liquid
2. Qualitative and quantitative composition
Each 5ml contains 500mg of Hydrotalcite light and 125mg of Dimethicone (activated)
3. Pharmaceutical form
Suspension
4. Clinical particulars
4.1 Therapeutic indications
Altacite Plus Suspension is indicated for the symptomatic relief of the following conditions: - Dyspepsia: flatulence and abdominal: hyperacidity; gastritis: peptic ulceration; heartburn especially when associated with oesophagitis or hiatus hernia and heartburn and pregnancy.
4.2 Posology and method of administration
Route of administration: Oral
Adults
10ml suspension between meals and at bedtime.
Elderly:
No specific recommendations in the elderly.
Children (8-12 years)
Half the adult dose.
4.3 Contraindications
None known
4.4 Special warnings and precautions for use
None Known
4.5 Interaction with other medicinal products and other forms of interaction
Altacite Plus may reduce intestinal absorption of tetracycline's
4.6 Pregnancy and lactation
For Co-simalcite 125/500 no clinical data on exposed pregnancies are available
Caution should be exercised when prescribing to pregnant women
4.7 Effects on ability to drive and use machines
Not applicable
4.8 Undesirable effects
Side effects are uncommon. Diarrhoea and vomiting have been reported but have ceased on withdrawal of the therapy.
4.9 Overdose
Overdose has not been reported. There is no evidence of absorption of Hydrotalcite in man. Investigations in healthy human volunteers have shown no elevation of serum aluminium or magnesium levels on administration of Hydrotalcite at therapeutic dosage for a continuous period of 28 days.
5. Pharmacological properties
5.1 Pharmacodynamic properties
Dimethicone is inert oil, which is tissue adherent and water repellent, it is therefore a mucosal protective and anti-foaming agent, which can reduce flatulence.
5.2 Pharmacokinetic properties
No data on pharmacokinetic studies of Altacite Plus Suspension are available. The active ingredients imethicone and activated imethicone are not generally absorbed.
5.3 Preclinical safety data
There are no preclinical data of relevance to the prescriber, which are additional to that already included in the other sections of the SmPC.
6. Pharmaceutical particulars
6.1 List of excipients
Sodium carboxymethylcellulose, tween 80, sorbitan mono-oleate, sorbitan tristearate, glyceryl monostearate, aerosil, methylcellulose 2500, microcystalline cellulose, bronopol, spearmint polvaromas 077, saccharin sodium, chloroform and purified water.
6.2 Incompatibilities
None known
6.3 Shelf life
3 years. After first opening the container, discard the contents 28 days after opening.
6.4 Special precautions for storage
Store between 4°C and 25°C
6.5 Nature and contents of container
High-density polyethylene bottles with standard jaypour caps or amber glass bottles with tamper evident polyethylene screw cap fitted with a polyethylene coated wool seal. Bottle of 500ml as a pharmacy item or 100ml (and 250ml) as a general sales item.
6.6 Special precautions for disposal and other handling
Not applicable
7. Marketing authorisation holder
Peckforton Pharmaceuticals Ltd.
Crewe Hall Crewe,
Cheshire,
CW1 6UL
8. Marketing authorisation number(s)
PL 15760/0002
9. Date of first authorisation/renewal of the authorisation
03/06/1999/10/09/2004
10. Date of revision of the text
31/3/2015